During this time, HIPRA brought together over 30 professionals from the Canadian swine sector at these three sessions, the main focus of which was a practical review of the most common reproductive problems in sows.
Jennifer Patterson (Swine Research Coordinator, University of Alberta) opened the sessions with a talk that focused on gilt management, summarising all the factors that can affect production parameters on a commercial farm. Isaac Rodríguez Ballarà (Regional Technical & Marketing Manager, Hipra) then presented a new approach to controlling infectious reproductive problems, covering their diagnosis, management, control and prevention under field conditions.
To conclude the sessions, Agustí Camprodon (Brand Manager, Hipra) presented a new vaccine that protects against reproductive losses due to Swine Erysipelas and Porcine Parvovirus: ERYSENG® PARVO.
It uses Hipramune® Gd, a state-of-the-art aqueous adjuvant based on ginsenosides to provide highly-protective and long-lasting immunity for the breeding herd. ERYSENG® PARVO has an exceptional efficacy against Swine Erysipelas, providing 6 months of immunity and reducing clinical signs of the disease in sows. It also offers wide protection against Porcine Parvovirus to cover the entire gestation period.
In addition to this, from 9 to 11 January 2018, HIPRA attended the Banff Pork Seminar held in Banff (Alberta). This seminar brought together over 750 delegates from different parts of Canada and the United States. Ramon Jordà (Product Manager, Hipra) presented two posters comparing the safety assessment and the humoral immune response elicited by ERYSENG® PARVO and its main competitors.
With the launch of ERYSENG® PARVO and participation at the Banff Pork Seminar, HIPRA consolidates the SENG range as "the most modern range of vaccines for breeders", and reinforces its commitment to continue growing as the Reference in Prevention for Animal Health.
